Sign in
ADAP Stock Price, Chart, Stats & News
Adaptimmune Therapeutics plc
Save
75.16M
Market cap
–
Current P/E
–
Forward P/E
ADAP chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.81% |
Operating margin | -252.32% |
Pretax margin | -251.58% |
Net margin | -260.82% |
Effective tax rate | -0.45% |
ROA | -129.95% |
ROE | 4103.11% |
D/E | -0.69x |
Interest coverage ratio | -28.99x |
ADAP valuation
P/E | – |
P/S | 1.15x |
P/B | -0.18x |
P/CF | -0.07x |
P/FCF | -0.39x |
P/OCF | -0.07x |
PEG | 0.00x |
EV multiple | -0.35x |
About
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies. Its primary focus is on addressing solid tumors in patients across the United States and the United Kingdom. At the core of its approach is the specific peptide enhanced affinity receptor (SPEAR) T-cell platform, designed to precisely identify cancer targets.
Similar securities
Based on sector and market capitalization
Report issue